Patient in focus: Diaverum at ERA/EDTA 2014 in Amsterdam

Renal care provider presents science and service portfolio at European congress

Munich / Amsterdam, 30 May 2014 – Diaverum, one of the world’s leading renal care providers, is presenting its service portfolio and the results of its latest research at the ERA/EDTA 2014 in Amsterdam. The global provider cares for 24,000 patients in more than 290 kidney centres in Europe, Middle East, Latin America and Australia.

“The ERA/EDTA is a key annual venue for Diaverum with strong focus on the science of nephrology and also an important place for us to meet with partners and the leading physicians from around the world. The insights won at ERA/EDTA and the networks built are essential for us on our way to become a true integrated renal care provider”, said Dag Andersson, CEO and President of Diaverum.

“We perform scientific activities based on the needs and the demands of the patients. We are very active in world-class clinical research with a strong patient focus to improve our practices and understanding of the complex needs of renal patients,” explained Prof. Giovanni Strippoli, Senior Vice President Scientific Affairs at Diaverum. “By doing our scientific studies, we aim to improve the quality of life of patients with renal diseases. Presenting the results of our scientific studies at the congress has the goal of open disclosing of study results and also inspiring renal clinicians, scientists and providers to increase the focus on research and the patient”.

Diaverum will present posters, speeches and showcase the service portfolio at the exhibition - with a clear focus on the patient.

Posters
Diaverum will present three posters at the ERA/EDTA 2014:

• Association Of Periodontitis With All-Cause And Cardiovascular Mortality In Adults With End-Stage Kidney Disease: A Multinational Cohort Study (G. Strippoli, On behalf of the ORAL-D Investigators)-presented by Giovanni Strippoli
• Association Of Surrogate Endpoints (Serum Parathyroid Hormone, Calcium And Phosphorus) With Mortality In Chronic Kidney Disease Trials: A Meta-Analysis (S. Palmer, A. Teixeira-Pinto, V. Saglimbene, P. Macaskill, J. Craig, G. Strippoli)-Presented by Marinella Ruospo
• Effect Of Aldosterone Antagonists On Ckd Progression: A Meta-Analysis (D. Bolignano, S. Palmer, S. Navaneethan, G. Strippoli )-Attended by Giovanni Strippoli

Speeches
Prof. Giovanni Strippoli, Senior Vice President Scientific Affairs at Diaverum and chairman of the Diaverum Academy will give a speech on behalf of the ORAL-D-Investigators about “Dental Health and Risk of all-cause and cardiovascular Mortality in Adults with End-Stage Kidney Disease: A Multinational Cohort Study”.
ORAL-D is the largest worldwide cross-sectional and prospective cohort study which looks at the prevalence of dental, periodontal, oral mucosa and salivary gland abnormalities in people on haemodialysis.

On Saturday, 31 May, 10.30-12.45, Dr. Staffan Schön, Vice President Quality Assurance and Regulatory Affairs at Diaverum, will talk about on “The Swedish Renal Registry – a source of epidemiological research” as part of the CME Course 7 “Cross-talks in renal epidemiology”.

Exhibition
The Diaverum booth is situated in hall1 in the RAI congress centre in Amsterdam, booth number B28.

The exhibition starts on Saturday, 31 May at 7pm CET and ends on Tuesday, 3 June, 13.30. Visitors are welcome to learn more about Diaverum and to meet the Diaverum experts and the top management team.

Press Contact
Ulrike Beringer
Corporate Communications Diaverum
E-mail: Ulrike.Beringer@diaverum.com
Phone: + 49 / 89 45 2444 124

About Diaverum
Diaverum is a global integrated renal care provider with a clear patient focus. As one of the world’s leading renal care providers we stand for excellent medical quality, renal care services and a patient-centred research. Being product-independent also gives us the flexibility to offer individual treatments for the individual needs of our patients and by coordinating our patients’ healthcare needs, we are improving their quality of life. At the same time we are creating value in the healthcare system by optimising the use of healthcare budgets — for the benefit of the patient and the society. Our experience in renal care dates back more than 20 years, when the first dialysis clinic was established, under the former name Gambro Healthcare, defining our Swedish roots. Today almost 8,000 employees care for more than 26,000 patients in 18 countries in Europe, Latin America, Middle East and Australia. The corporate office is located in Munich, Germany.  www.diaverum.com

Tags: